Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/22/23 | 8-K | Current report filing |
|
   |
3 |
| 08/22/23 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
2 | |
| 08/21/23 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
6 | |
| 08/14/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
23 |
| 08/14/23 | 8-K | Current report filing |
|
|
5 |
| 08/09/23 | EFFECT | Notice of Effectiveness |
|
1 | |
| 08/09/23 | 424B4 | Prospectus filed pursuant to Rule 424(b)(4) |
|
8 | |
| 08/07/23 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 08/07/23 | ARS | Annual report to security holders |
|
127 | |
| 08/07/23 | DEF 14A | Definitive proxy statements |
|
20 |
